Skip to main content
OpenTrials
Completed

NCT Number: NCT07269275

HLA Eplet Mismatches to Predict Long-term Kidney Transplant Outcomes

Human leukocyte antigen (HLA) matching evaluates the degree of compatibility between donors and organ transplant recipients and assesses broad antigen differences that may influence immune responses post-transplant. A refined HLA matching method based on examining clusters of amino acids on HLA molecules, named eplets, has been recently developed. This method identifies immunogenic discrepancies that may not be apparent through traditional HLA matching. In recent years, assessment of HLA eplet mismatches has emerged as a promising strategy to improve immune risk stratification in kidney transplantation, which is crucial for kidney recipients' management and maximizing allograft longevity. Despite its potential, the prognostic value and clinical relevance of HLA eplet mismatches for predicting long-term kidney allograft failure has not been robustly demonstrated.

In this study, the investigators aim to investigate whether HLA eplet mismatches may represent a relevant clinical tool for patient risk stratification and prediction of long-term allograft failure beyond standard clinical, histological and immunological parameters for monitoring in kidney transplant recipients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Paris Translational Research Center for Organ Transplantation

Paris, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Living or deceased donor kidney recipients transplanted after 2004
  • Kidney recipients older than 18 years of age
  • Kidney recipients with available HLA genotyping data

Exclusion criteria

  • Combined transplantation

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. Kidney allograft failure

    Time frame: Up to 10 years after kidney transplantation

Secondary outcomes

  1. Added prognostic value

    Time frame: Up to 10 years after kidney transplantation

    Added prognostic value of HLA eplet mismatches over standard of care monitoring of kidney transplant recipients based on clinical, histological, immunological parameters

Sponsors and collaborators

Lead sponsor

Paris Translational Research Center for Organ Transplantation

Other

Registry information

Official study title

Prognostic Value of HLA Eplet Mismatches for Long-term Kidney Transplant Outcomes

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Dec 8, 2025
Registry last updated
Dec 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.